ORIGINAL RESEARCH

L.A. Gray
A. Ehteshami Rad
J.R. Gaughen, Jr.
T.J. Kaufmann
D.F. Kallmes

Efficacy of Percutaneous Vertebroplasty for Multiple Synchronous and Metachronous Vertebral Compression Fractures

BACKGROUND AND PURPOSE: Limited data exists regarding the efficacy of percutaneous vertebroplasty for multiple synchronous and metachronous vertebral compression fractures. The purpose of this study was to evaluate whether the number of vertebral levels treated during percutaneous vertebroplasty procedures or the number of separate vertebroplasty procedures performed on a given patient affect clinical outcomes.

MATERIALS AND METHODS: We defined 3 patient populations in our retrospective study. Group 1 included 328 patients who underwent 1 single-level vertebroplasty procedure. Group 2 included 226 patients who underwent a single procedure in which 2 or more vertebral levels were treated. Group 3 included 101 patients who underwent 2 or more separate vertebroplasty procedures. Follow-up was performed between 1 week and 2 years postoperatively. Clinical outcomes were assessed through analysis of quantitative measurements of pre- and postoperative levels of pain with and without activity (0–10) as well as mobility improvement. The Kruskal-Wallis rank sum test was used to evaluate the differences among groups. Univariate and χ^2 analyses were performed to show the proportion of underlying diseases in each group.

RESULTS: Mean pain improvement with/without activity at 2-year follow-up was 5.8/3, 4.9/3.7, and 5.4/3.1 in groups 1, 2, and 3, respectively; and mean mobility improvement in 2-year follow-up was 0.67, 0.63, and 0.65 for groups 1, 2, and 3, respectively.

CONCLUSIONS: There was no significant difference in pain relief and mobility improvement in patients treated for multiple synchronous or metachronous vertebral compression fractures in comparison with those treated for solitary isolated fractures.

Percutaneous vertebroplasty appears to be an effective minimally invasive procedure used to treat painful vertebral compression fractures. The procedure, originally used in patients with vertebral malignancies and hemangiomas, has been expanded in its therapeutic range to include osteoporotic fractures refractory to medical management. Many patients with vertebroplasty return after their initial procedure with new fractures.^{1–8} Treatment in these returning patients commonly involves cement injection into multiple vertebral levels in multiple separate procedures to address the synchronous and metachronous fractures inherent in osteoporotic spines.

The purpose of this study was to evaluate whether the number of vertebral levels treated during percutaneous vertebroplasty procedures or the number of separate procedures performed on each patient affected clinical outcomes. By doing so, we attempted to correlate the severity and extent of disease with therapeutic benefit of vertebroplasty.

Materials and Methods

Patient Selection

We conducted a retrospective review of consecutive percutaneous vertebroplasty procedures performed at our institution between February 1999 and February 2007 to define 3 patient populations. We

have previously published global outcomes in this same cohort of patients as well as many subgroup analyses.^{6,9–23} We have never previously analyzed this same cohort of patients regarding the impact of the number of treated levels or treatment sessions on outcome. We defined these groups as:

- Group 1: Patients who underwent 1 single-level vertebroplasty procedure.
- Group 2: Patients who underwent a single procedure in which 2 or more vertebral levels were treated.
- Group 3: Patients who underwent 2 or more separate vertebroplasty procedures.

Preprocedural Work-Up

Screening and preprocedural evaluation have been described in detail by Jensen et al²⁴ and Maynard et al.²⁵ Briefly, patients with subacute pain with corresponding fractures were considered appropriate candidates. Patients with fractures of uncertain age or with atypical pain patterns were treated if MR imaging or bone scanning demonstrated edema or increased activity, respectively.²⁵

Procedural Technique and Materials

The vertebroplasty technique has been described in detail previously. Briefly, a unilateral or bilateral transpedicular approach is used to place the tip of an 11-gauge needle or needles in the ventral aspect of the vertebra. Using continuous lateral fluoroscopy, we inject barium-opacified polymethylmethacrylate until extraosseous extravasation or filling of the posterior aspect of the vertebra is attained.

Assessment

Clinical Outcomes. Patients were assessed before the procedure regarding the degree of pain and limitations of mobility. Patients in

Received July 16, 2008; accepted after revision August 15.

From the Department of Radiology (L.A.G., A.E.R., T.J.K., D.F.K.), Mayo Clinic, Rochester, Minn; and Department of Radiology (J.R.G.), University of Virginia Health Services, Charlottesville, Va.

Please address correspondence to David F. Kallmes, MD, Department of Radiology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905; e-mail: kallmes.david@mayo.edu

DOI 10.3174/ajnr.A1328

group 3 were followed up separately for each procedure on postoperative day 1 and at 1 week, 1 month, 6 months, 1 year, and 2 years postoperatively. Procedural notes were also reviewed to evaluate procedural complications.

Pain. Pain was assessed by using an ordinal scale, in which the patients were asked to rate their pain on a scale of 0–10, with 0 representing no pain and 10 representing the “most pain ever experienced.” Questions were posed as pain at rest and pain with activity. A Roland-Morris Disability Questionnaire score was obtained by experienced vertebroplasty nurses and neuroradiologists.

Mobility. Mobility was assessed before the procedure by using a 4-point scale as follows: walking >1 block, walking <1 block, restricted (with the help of walker or walking around the home but not outside), and bedridden. We tracked the patients in all 3 groups as to whether there was improvement, no change, or decreased mobility after the procedure. We assigned the following numbers to calculate the quantity of mobility changes: improvement = 1, no change = 0, and decreased = −1.

Underlying Causes

We categorized the underlying causes for all vertebral fractures into 3 groups: trauma; neoplasm, to include multiple myeloma; and osteoporosis. Baseline pain and disability as well as severity throughout follow-up were compared among groups.

Statistical Analysis

Clinical Outcome. The Kruskal-Wallis rank sum test was used to evaluate a statistically significant difference among the 3 groups in pre- and postoperative levels of pain and mobility. Because the *P* value was calculated for each follow-up time point (5 times), we performed a Bonferroni adjustment for *P* value, and <.01 was considered significant. When a *P* value < .01 was obtained, we used a 2-tailed Wilcoxon rank sum test to evaluate statistically significant differences between individual groups. Such an approach was performed on the pre- and postoperative levels of pain and mobility for the 3 groups in an attempt to preserve the operant form of the data. A χ^2 test was performed to compare the proportion of underlying processes, including trauma, osteoporosis, and neoplasm, including multiple myeloma, among groups. Univariate analysis showed the differences in the severity of pain caused by underlying diseases in each group.

Results

Patient Population

We identified 655 patients (67% female) treated at 1195 vertebral levels during 791 vertebroplasty procedures. Demographic details of the groups are shown in Table 1.

Preoperative Evaluations

Proportions of underlying processes in each group are shown in Table 2. Among patients with cancer, baseline pain was higher than among those without cancer in group 1. Among patients with osteoporosis, preoperative pain was less with activity in group 2 than among those patients without osteoporosis.

Clinical Outcome

Table 3 shows the available number of patients at the various follow-up periods.

Table 1: Patient demographics

	Group 1	Group 2	Group 3
No. of patients (female %)	328 (70%)	226 (64%)	101 (66%)
Mean age by year (SD)	75 (11)	74 (12)	73 (11)
Median % of available patients in different follow-up time points (range)	68% (22%–93%)	70% (32%–92%)	70% (26%–93%)
No. of levels	328	539	328
Upper thoracic (T1–T4)	1 (0.5%)	8 (1%)	7 (2%)
Mid thoracic (T5–T8)	64 (19.5%)	85 (16%)	55 (17%)
Lower thoracic (T9–T12)	100 (30.5%)	171 (32%)	112 (34%)
Upper lumbar (L1–L3)	125 (38%)	199 (37%)	115 (35%)
Lower lumbar (L4–L5)	35 (10.5%)	76 (14%)	38 (11.5%)
Sacroplasty	3 (1%)	0	1 (0.5%)

Table 2: Proportion (%) of underlying disease in groups

	Group 1	Group 2	Group 3
Trauma	13%*	6%	4%
Neoplasm	11%	15%	9%
Osteoporosis	76%	79%	87%

* Significantly higher than the 2 other groups.

Table 3: Number of available patients or (procedures) in each follow-up time point

	Group 1 (%)	Group 2 (%)	Group 3 (%)*	All Groups (%)*
1 Week	306 (93)	208 (92)	222 (94)	736 (93)
1 Month	262 (80)	177 (78)	188 (79)	627 (79)
6 Months	224 (68)	158 (70)	175 (74)	557 (70)
1 Year	197 (60)†	112 (50)	109 (46)†	418 (53)
2 Years	73 (22)	73 (32)	61 (26)	207 (26)

* Number of procedures.

† Number of available patients is significantly different.

Pain. Figures 1 and 2 show the severity of pain with time, both at rest and with activity, respectively. Because we have published in previous articles for the entire cohort,^{6,20} we noted significant improvement in pain at all time points compared with preprocedural pain severity both at rest and with activity. There were no significant differences in pain severity among groups at any time point either at rest or with activity. At 6-month follow-up, there were no significant differences in the severity of pain as a function of underlying disease processes, including trauma, osteoporosis, or cancer.

Back-Pain-Specific Function. Scores on the Roland Morris Disability Scale are shown in Fig 3. There were no significant differences among groups at any time point.

Mobility. Figure 4 shows the improvement of mobility in all groups. Scoring assignments are the following: improvement = 1, no change = 0, and decrease = −1. There were no differences noted.

Complications

Immediate and long-term (in 2-year follow-up) complications are shown in Table 4. There were no significant differences between the 3 groups for incident fractures (*P* = .06).

Group 3 Specifications. Patients in group 3 underwent a median of 2 procedures (range, 2–7) with a median delay of 88 days (range, 1–2131 days) from the previous procedure. The

Fig 1. Graph shows changes of pain scores (0–10) at rest. Pre-op indicates preoperative.

Fig 2. Graph shows changes of pain scores (0–10) with activity. Pre-op indicates preoperative.

mean time interval between procedures in group 3 was 257 days.

Power of the Study. Our data had 80% power to detect an effect size of 0.014 for 1-month pain at rest and with activity and 0.014 for 1-month Roland-Morris Disability score.

Discussion

Vertebroplasty was initially applied in patients with well-documented single-level osteoporotic compression fractures.²⁴ With increasing dissemination of the procedure, many groups now routinely treat multiple vertebral levels in a single session. Furthermore, many patients return for additional treatments at later time points for new-onset fractures. The aim of this study was to evaluate whether more extensive procedures, including treatment of multiple synchronous and metachro-

nous fractures, were as effective as single-level procedures in relieving pain and improving mobility.

The results of this study indicate that outstanding pain relief is consistently achieved with percutaneous vertebroplasty, regardless of either the number of fractures treated in 1 procedure or the number of treatment sessions. Specifically, mean decrease in pain and improvement in back-pain-specific morbidity were similar across all groups described in this report. These data support the routine use of multilevel vertebroplasty as well as the routine application of vertebroplasty in patients returning with new-onset fractures.

Current medical literature offers numerous case series and retrospective studies that have reported overwhelmingly positive clinical responses to percutaneous vertebroplasty.^{1,2,6,26–30} The bulk of this research has centered around

Fig 3. Graph shows Roland-Morris Disability pain scores. Pre-op indicates preoperative.

Fig 4. Graph shows mobility improvement during the time in different groups.

evaluations of the safety and efficacy of the procedure. Some series report clinical benefit in as many as 97% of patients,³¹ with the procedure producing exceedingly few clinically apparent complications.^{2,26,30,32-34} Other case series have focused on patient-selection criteria in an attempt to aid in maximizing the potential of vertebroplasty.³⁵⁻³⁸ To our knowledge, however, no literature exists that correlates clinical outcomes with extent or severity of disease. Specifically, none of these previous series has evaluated whether the efficacy of vertebroplasty is affected by the number of vertebrae treated in a given session. Similarly, previous studies have not evaluated whether patients returning for additional treatment sessions for new fractures derive the same benefit as those needing treatment only once.

Table 4: Percentage of complications in the 3 groups

	Group 1 (%)	Group 2 (%)	Group 3 (%)*
Cement embolus to pulmonary vasculature without clinical sequelae	1	1	1
Cement embolus to epidural vein without clinical sequelae	3	4	8
Failure of infusion of adequate cement volume	1	1	1
Disk space cement injection	10	13	14
Paravertebral cement injection	6	10	6
Incident fracture	12	16	19

* Number of procedures.

Although this study represents an objective evaluation of the efficacy of vertebroplasty over a diverse patient population, it has several limitations. Its retrospective nature lacks the randomization of a prospective clinical trial. Also, as mentioned previously, selection bias may have affected the outcome of patients returning for multiple procedures.

The results of this study suggest that percutaneous vertebroplasty represents an effective treatment for vertebral compression fractures, regardless of the severity or extent of disease. Future studies would aid in furthering our understanding of the diversity of the patient population currently receiving benefit from the procedure. Prospective randomized trials may assist in clarifying the uncertainties that continue to surround the use of this technique with regard to prognostication of clinical outcomes. Similarly, long-term studies may aid in delineating the clinical benefit bestowed on these patients.

Conclusions

There were no significant differences in pain relief and mobility improvement in patients treated for multiple synchronous or metachronous vertebral compression fractures compared with those treated for solitary isolated fractures.

References

1. Amar AP, Larsen DW, Esnaashari N, et al. **Percutaneous transpedicular polymethylmethacrylate vertebroplasty for the treatment of spinal compression fractures.** *Neurosurgery* 2001;49:1105–14, discussion 1114–05
2. Grados F, Depriester C, Cayrolle G, et al. **Long-term observations of vertebral osteoporotic fractures treated by percutaneous vertebroplasty.** *Rheumatology (Oxford)* 2000;39:1410–14
3. Kim SH, Kang HS, Choi JA, et al. **Risk factors of new compression fractures in adjacent vertebrae after percutaneous vertebroplasty.** *Acta Radiol* 2004;45:440–45
4. Jensen ME, Dion JE. **Percutaneous vertebroplasty in the treatment of osteoporotic compression fractures.** *Neuroimaging Clin N Am* 2000;10:547–68
5. Kobayashi K, Shimoyama K, Nakamura K, et al. **Percutaneous vertebroplasty immediately relieves pain of osteoporotic vertebral compression fractures and prevents prolonged immobilization of patients.** *Eur Radiol* 2005;15:360–67
6. Layton KF, Thielen KR, Koch CA, et al. **Vertebroplasty, first 1000 levels of a single center: evaluation of the outcomes and complications.** *AJNR Am J Neuroradiol* 2007;28:683–89
7. Syed MI, Patel NA, Jan S, et al. **Intradiskal extravasation with low-volume cement filling in percutaneous vertebroplasty.** *AJNR Am J Neuroradiol* 2005;26:2397–401
8. Voormolen MH, Lohle PN, Juttman JR, et al. **The risk of new osteoporotic vertebral compression fractures in the year after percutaneous vertebroplasty.** *J Vasc Interv Radiol* 2006;17:71–76
9. Rad AE, Gray LA, Kallmes DF. **Significance and targeting of small, central clefts in severe fractures treated with vertebroplasty.** *AJNR Am J Neuroradiol* 2008;29:1285–7. Epub 2008 Apr 16
10. McDonald RJ, Trout AT, Gray LA, et al. **Vertebroplasty in multiple myeloma: outcomes in a large patient series.** *AJNR Am J Neuroradiol* 2008;29:642–48
11. Koch CA, Layton KF, Kallmes DF. **Outcomes of patients receiving long-term corticosteroid therapy who undergo percutaneous vertebroplasty.** *AJNR Am J Neuroradiol* 2007;28:563–66
12. Kallmes DF. **Percutaneous vertebroplasty causing an increase in retropulsion of bone fragments.** *J Vasc Interv Radiol* 2007;18:1333–34
13. Trout AT, Kallmes DF, Layton KF, et al. **Vertebral endplate fractures: an indicator of the abnormal forces generated in the spine after vertebroplasty.** *J Bone Miner Res* 2006;21:1797–802
14. Trout AT, Kallmes DF, Lane JI, et al. **Subsequent vertebral fractures after vertebroplasty: association with intraosseous clefts.** *AJNR Am J Neuroradiol* 2006;27:1586–91
15. Trout AT, Kallmes DF, Kaufmann TJ. **New fractures after vertebroplasty: adjacent fractures occur significantly sooner.** *AJNR Am J Neuroradiol* 2006;27:217–23
16. Trout AT, Kallmes DF. **Does vertebroplasty cause incident vertebral fractures? A review of available data.** *AJNR Am J Neuroradiol* 2006;27:1397–403
17. Kaufmann TJ, Trout AT, Kallmes DF. **The effects of cement volume on clinical outcomes of percutaneous vertebroplasty.** *AJNR Am J Neuroradiol* 2006;27:1933–37
18. Kallmes DF. **Randomized vertebroplasty trials: current status and challenges.** *Acad Radiol* 2006;13:546–49
19. Trout AT, Kallmes DF, Gray LA, et al. **Evaluation of vertebroplasty with a validated outcome measure: the Roland-Morris Disability Questionnaire.** *AJNR Am J Neuroradiol* 2005;26:2652–57
20. Trout AT, Gray LA, Kallmes DF. **Vertebroplasty in the inpatient population.** *AJNR Am J Neuroradiol* 2005;26:1629–33
21. Dansie DM, Luetmer PH, Lane JI, et al. **MRI findings after successful vertebroplasty.** *AJNR Am J Neuroradiol* 2005;26:1595–600
22. Kaufmann TJ, Wald JT, Kallmes DF. **A technique to circumvent subcutaneous cement tracts during percutaneous vertebroplasty.** *AJNR Am J Neuroradiol* 2004;25:1595–96
23. Rad AE, Kallmes DF. **Pain relief following vertebroplasty in patients with and without localizing tenderness on palpation.** *AJNR Am J Neuroradiol* 2008;29:1622–26
24. Jensen ME, Evans AJ, Mathis JM, et al. **Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects.** *AJNR Am J Neuroradiol* 1997;18:1897–904
25. Maynard AS, Jensen ME, Schweickert PA, et al. **Value of bone scan imaging in predicting pain relief from percutaneous vertebroplasty in osteoporotic vertebral fractures.** *AJNR Am J Neuroradiol* 2000;21:1807–12
26. Diamond TH, Bryant C, Browne L, et al. **Clinical outcomes after acute osteoporotic vertebral fractures: a 2-year non-randomised trial comparing percutaneous vertebroplasty with conservative therapy.** *Med J Aust* 2006;184:113–17
27. Evans AJ, Jensen ME, Kip KE, et al. **Vertebral compression fractures: pain reduction and improvement in functional mobility after percutaneous polymethylmethacrylate vertebroplasty retrospective report of 245 cases.** *Radiology* 2003;226:366–72
28. Legroux-Gerot I, Lormeau C, Boutry N, et al. **Long-term follow-up of vertebral osteoporotic fractures treated by percutaneous vertebroplasty.** *Clin Rheumatol* 2004;23:310–17
29. Alvarez L, Alcaraz M, Perez-Higueras A, et al. **Percutaneous vertebroplasty: functional improvement in patients with osteoporotic compression fractures.** *Spine* 2006;31:1113–18
30. Anselmetti GC, Corgnier A, Debernardi F, et al. **Treatment of painful compression vertebral fractures with vertebroplasty: results and complications.** *Radiol Med (Torino)* 2005;110:262–72
31. McGraw JK, Lippert JA, Minkus KD, et al. **Prospective evaluation of pain relief in 100 patients undergoing percutaneous vertebroplasty: results and follow-up.** *J Vasc Interv Radiol* 2002;13:883–86
32. Hacin-Bey L, Baisden JL, Lemke DM, et al. **Treating osteoporotic and neoplastic vertebral compression fractures with vertebroplasty and kyphoplasty.** *J Palliat Med* 2005;8:931–38
33. Kallmes DF, Schweickert PA, Marx WF, et al. **Vertebroplasty in the mid- and upper thoracic spine.** *AJNR Am J Neuroradiol* 2002;23:1117–20
34. Mathis JM. **Percutaneous vertebroplasty.** *JBR-BTR* 2003;86:299–301
35. Cotten A, Boutry N, Cortet B, et al. **Percutaneous vertebroplasty: state of the art.** *Radiographics* 1998;18:311–20, discussion 320–13
36. Alvarez L, Perez-Higueras A, Granizo JJ, et al. **Predictors of outcomes of percutaneous vertebroplasty for osteoporotic vertebral fractures.** *Spine* 2005;30:87–92
37. McGraw JK, Cardella J, Barr JD, et al. **Society of interventional radiology quality improvement guidelines for percutaneous vertebroplasty.** *J Vasc Interv Radiol* 2003;14:S311–15
38. Syed MI, Shaikh A. **Vertebroplasty: a systematic approach.** *Pain Physician* 2007;10:367–80